Innovative Proprietary/Licensed Products
Undisclosed
VariousActive
Key Facts
About Laboratorios Farmaceuticos Rovi
Laboratorios Farmaceuticos Rovi is a publicly traded Spanish pharmaceutical company with a dual business model combining proprietary drug development and contract manufacturing. The company has demonstrated significant growth, reporting €743.5 million in operating revenue for 2025, driven by its specialty pharmaceuticals and CDMO segments. Rovi is strategically investing in R&D, with expenses increasing 47% in 2025, and has established key international partnerships, including a major collaboration with Roche. Its operations span over 60 countries, supported by four manufacturing plants.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| ASPEN Study Program | Insmed | Phase 3 |
| ARISE Study Program | Insmed | Phase 3 |
| MGL-2086 | Madrigal Pharmaceuticals | Phase 1 |
| Undisclosed Partnered Program | Septerna | Discovery |
| Undisclosed Cell Therapy | Immix Biopharma | Pre-clinical |
| HTL0039732 | Nxera Pharma | Preclinical |
| LYT-310 | PureTech Health | Preclinical |
| Bispecific (Undisclosed) | MacroGenics | Preclinical |
| Sec61 Portfolio Assets | Kezar Life Sciences | Preclinical |
| WTX-518 | Werewolf Therapeutics | Preclinical |
| WTX-712 | Werewolf Therapeutics | Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |